In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
11h
Stockhead on MSNCrucible: This rare blood disease tackler plans to hit investors with its best shotThe myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...
The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results